Positionspapier vom 27.01.2021 – COVID-19-Schutzimpfung bei PatientInnen mit aktiver Krebserkrankung

Die Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), die Deutsche Gesellschaft für Senologie (DGS) sowie die Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) sind an einem Positionspapier zur COVID-19-Schutzimpfung bei PatientInnen mit aktiver Krebserkrankung beteiligt, das federführend von der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) erarbeitet wurde.

Publikationsverlauf

Artikel online veröffentlicht:
14. April 2021

• Literatur

• 1 WHO Coronavirus Disease (COVID-19) Dashboard. Data last updated: 2021/1/26, 4 : 50 pm CET. Online: https://covid19.who.int/
• 2 Online: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/nCoV_node.html;jsessionid=57B91F291A3125A8213D01E6115FE532.internet081
• 3 Online: https://www.dgim.de/fileadmin/user_upload/PDF/Publikationen/Archiv/Positionspapiere_und_Stellungnahmen/FINAL_DGIM_20210107_Stellungnahme_STIKO-COVID-19.pdf
• 4 Giesen N, Sprute R, Maria Rührich M. et al. Evidence-based Management of COVID-19 in Cancer Patients – Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer 2020; 140: 86-104 doi:10.1016/j.ejca.2020.09.009
• 5 Von Lilienfeld-Toal M, Giesen N, Greinix H. et al. Coronavirus-Infektion (COVID-19) bei Patienten mit Blut- und Krebserkrankungen. Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status Januar 2021. Online: https://www.onkopedia.com/de/onkopedia/guidelines/coronavirus-infektion-covid-19-bei-patienten-mit-blut-und-krebserkrankungen/@@guideline/html/index.html
• 6 Cook G, John Ashcroft A, Pratt G. et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol 2020; 190: e83-e86 doi:10.1111/bjh.16874
• 7 Dai M, Liu D, Liu M. et al. Patients With Cancer Appear More Vulnerable to SARS-COV-2: A Multicenter Study During the COVID-19 Outbreak. Cancer Discov 2020; DOI: 10.1158/2159-8290.CD-20-0422.
• 8 Grivas P, Warner JL, Shyr Y. et al. Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19). Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
• 9 Kuderer NM, Choueiri TK, Shah DP. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 2020; 395: 1907-1918 doi:10.1016/S0140-6736(20)31187-9
• 10 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-337 doi:10.1016/S1470-2045(20)30096-6
• 11 Mehta V, Goel S, Kabarriti R. et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discov 2020; DOI: 10.1158/2159-8290.CD-20-0516.
• 12 Palmieri C, Turtle L, Docherty A. et al. Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. Ann Oncol 2020; 3 (Suppl. 04) S934-S973 doi:10.1016/annonc/annonc289 update January 2021 (personal communication)
• 13 Passamonti F, Cattaneo C, Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Hematol 2020; 7: e737-e747 doi:10.1016/S2352-3026(20)30251-9
• 14 Tian J, Yuan X, Xiao J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893-903 doi:10.1016/S1470-2045(20)30309-0
• 15 Wise-Draper T, Desai A, Elkrief A. et al. Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis. Ann Oncol 2020; 31 (Suppl. 04) S1142-S1215 doi:10.1016/annonc/annonc325
• 16 Saini KS, Tagliamento M, Lambertini M. et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer 2020; 139: 43-50 doi:10.1016/j.ejca.2020.08.011
• 17 COVID-19 and Cancer Consortium (CCC19). Online (Stand: 23.01.2021): https://public.tableau.com/profile/reboot.rx%23!/vizhome/covidcancer/PublishedClinicalStudies
• 18 Venkatesulu BP, Chandrasekar VT, Girdhar P. et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv 2020; DOI: 10.1101/2020.05.27.20115303.
• 19 Rüthrich MM, Giessen-Jung C, Borgmann S. et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2020; DOI: 10.1007/s00277-020-04328-4. update January 2021 (personal communication)
• 20 Online: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/02_21.pdf?blob=publicationFile
• 21 Williamson EJ, Walker AJ, Bhaskaran K. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430-436 doi:10.1038/s41586-020-2521-4
• 22 Wood WA, Neuberg DS, Thompson JC. et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv 2020; 4: 5966-5975 doi:10.1182/bloodadvances.2020003170
• 23 De Joode K, Dumoulin DW, Tol J. et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer 2020; 141: 171-184 doi:10.1016/j.ejca.2020.09.027
• 24 Bundesministerium für Gesundheit. Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2(Coronavirus-Impfverordnung–CoronaImpfV). Online: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/C/Coronavirus/Verordnungen/CoronaImpfV_-_De_Buette.pdf
• 25 Giesen N, Sprute R, Rüthrich M. et al. for the COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 Update of AGIHO guideline on evidence-based management of COVID-19 in cancer patients regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer 2021; 147: 154-160
• 26 Avanzato VA, Matson JM, Seifert SB. et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell 2020; 183: 1901-1912 doi:10.1016/j.cell.2020.10.049
• 27 Online: https://www.dgho.de/publikationen/stellungnahmen/gute-aerztliche-praxis/coronavirus/prolongierte-virusausscheidung-shedding-von-sars-cov-2_20201114.pdf/view